Adds Technology Capabilities to Accelerate Transformation
DANBURY, Conn.--(BUSINESS WIRE)--
IMS Health (NYSE:IMS), a leading global provider of information and
technology services to the healthcare and life sciences industries,
today completed its previously announced acquisition of certain customer
relationship management (CRM) and strategic data businesses of Cegedim.
The acquisition gives IMS Health powerful new tools to address growing
demand for end-to-end CRM, multi-channel marketing and master data
management solutions. It also establishes one of the world’s most robust
healthcare reference databases with insights on more than 14 million
healthcare professionals, and solidifies IMS Health as the partner of
choice for Real-World Evidence capabilities.
“Most importantly, through this acquisition we are thrilled to welcome
more than 4,500 new IMSers – highly skilled professionals with deep
technology and healthcare expertise,” said Ari Bousbib, chairman and
CEO, IMS Health. “Our global team across 100 countries offers an
unmatched combination of breadth and depth of capabilities to our 5,000+
clients worldwide.”
About IMS Health
IMS Health is a leading global information and technology services
company providing clients in the healthcare industry with comprehensive
solutions to measure and improve their performance. End-to-end
proprietary applications and configurable solutions connect 10+
petabytes of complex healthcare data through the IMS OneTM
cloud-based master data management platform, providing comprehensive
insights into diseases, treatments, costs and outcomes. The company’s
15,000 employees blend global consistency and local market knowledge
across 100 countries to help clients run their operations more
efficiently. Customers include pharmaceutical, consumer health and
medical device manufacturers and distributors, providers, payers,
government agencies, policymakers, researchers and the financial
community.
As a global leader in protecting individual patient privacy, IMS Health
uses anonymous healthcare data to deliver critical, real-world disease
and treatment insights. These insights help biotech and pharmaceutical
companies, medical researchers, government agencies, payers and other
healthcare stakeholders to identify unmet treatment needs and understand
the effectiveness and value of pharmaceutical products in improving
overall health outcomes. Additional information is available at www.imshealth.com.
IMSFIN
Source: IMS Health